Pharmaceuticals 2 January 2026

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.

5 January 2026

Health News·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.

5 January 2026

NASDAQ:STTX·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener

5 January 2026

Health News·NASDAQ:ARWR·Pharmaceuticals·Stock Market

Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

Abivax shares fell about 9.1% to $121.64 in midday U.S. trading on Monday, after touching $133.73 earlier in the session. The stock hit a low of $121.08, while its Paris-listed shares ended down 9.7%. Investing

5 January 2026

NASDAQ:ABVX·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session.

5 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Brand Engagement Network (BNAI) stock rises again premarket as AI pharma deal keeps traders hooked

Shares of Brand Engagement Network, Inc rose 5.3% to $3.97 in premarket trading on Monday, extending a sharp late-week rally in the thinly traded AI company. Public

5 January 2026

Artificial Intelligence·NASDAQ:BNAI·Pharmaceuticals·Stock Market

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price target to $5 from $3. The shares closed up 26.7% on Friday at $4.27. Investing

5 January 2026

NASDAQ:IRWD·Pharmaceuticals·Stock Market

GSK share price today: why the stock dipped after China approved Nucala for COPD

GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease. The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT. Investing

5 January 2026

LSE:GSK·Pharmaceuticals·Stock Market

Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

Merck & Co shares closed up 1.1% on Friday at $106.45, leaving the stock within sight of a 52-week high ahead of Monday’s U.S. market reopen. MarketWatch

5 January 2026

NASDAQ:CDTX·NYSE:MRK·Pharmaceuticals·Stock Market

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing

4 January 2026

NASDAQ:IRWD·Pharmaceuticals

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics, Inc. shares closed down 6.5% on Friday at $72.76, extending a losing streak to seven consecutive sessions as the U.S. market heads into the first full trading week of 2026. The stock is down about 13% since Dec. 23 and roughly 29% below the record intraday high of $103 hit in early December. Shares traded between $72.15 and $77.82 on Friday, with about 854,000 shares changing hands. Investing

4 January 2026

NASDAQ:KYMR·Pharmaceuticals

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Eli Lilly and Co shares ended Friday up $5.44, or 0.5%, at $1,080.36, giving the drugmaker a firm start to 2026 as investors positioned for a packed run of healthcare catalysts in January and February.

4 January 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

Bristol-Myers Squibb shares ended down 0.9% at $53.46 on Friday, after the company confirmed it will present at J.P. Morgan’s annual healthcare conference on Jan. 12. JPMorgan Chase

3 January 2026

NYSE:BMY·Pharmaceuticals·Stock Market

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer Inc shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday.

3 January 2026

Earnings Reports·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck & Co. shares ended Friday up about 1.2% at $106.45. Nasdaq said the cash tender offer for Cidara Therapeutics is scheduled to expire one minute after 11:59 p.m. ET on Jan. 6, with the merger tentatively slated to close before the market opens Jan. 7. The exchange said Cidara shares would be halted after the after-hours session on Jan. 6 and suspended Jan. 8 if the deal closes as planned. NASDAQ Trader

3 January 2026

NASDAQ:CDTX·NYSE:MRK·Pharmaceuticals·Stock Market

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend.

3 January 2026

NYSE:JNJ·NYSE:LLY·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50.

3 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot

Novavax Inc shares rose 6.1% on Friday to close at $7.13, outperforming in a mixed U.S. session as traders latched onto fresh signs of overseas demand for its updated COVID-19 shot. The stock traded about 38% below its 52-week high of $11.55 set on Jan. 7 last year, according to MarketWatch data. MarketWatch

3 January 2026

NASDAQ:NVAX·Pharmaceuticals·Stock Market

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Shares of Eli Lilly and Company rose about 0.5% in after-hours trading on Friday, last at $1,080.36. The stock swung between $1,052.96 and $1,080.49 during the regular session.

3 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

Dyne Therapeutics shares fell about 6% on Friday, giving back earlier gains in a volatile first session of 2026 for some biotech names. The Nasdaq-listed stock was down 6.1% at $18.36 in afternoon trading, after touching $20.90 at the high and $18.13 at the low.

2 January 2026

NASDAQ:DYN·Pharmaceuticals·Stock Market

Pharmaceuticals 2 January 2026 - 5 January 2026